IL-17F Monoclonal Antibody (SHLR17), Functional Grade, eBioscience™, Invitrogen™

Description

• Description: This SHLR17 monoclonal antibody reacts with human interleukin (IL)-17F
• IL-17F is a homodimeric, 34 kDa member of the IL-17 family, which includes IL-17(A), B, C, D, E (IL-25)
• Within this family, IL-17A and IL-17F are produced preferentially by T helper 17 (Th17) cells, with other members produced more widely
• IL-17F and IL-17A have many overlapping functions, but knockout studies have shown each to have independent functions as well
• In vitro cultured Th17 cells have been shown to express IL-17F and IL-17A homodimers and IL-17A/F heterodimers depending on the culture conditions and their differentiation state
• A heterodimer of IL-17RA and IL-17RC has been shown to bind IL-17F, resulting in target cell-secretion of pro-inflammatory cytokines and chemokines, as well as neutrophil recruitment
• This SHLR17 monoclonal antibody neutralizes the bioactivity of IL-17F homodimers without affecting IL-17A/F heterodimers
• Applications Reported: This SHLR17 monoclonal antibody inhibits the activity of human IL-17F
• Applications Tested: The ND50 of SHLR17, as measured by the inhibition of mouse IL-6 induction in NIH/3T3 cells, is 0.5-4 μg/mL in the presence of 1 μg/mL of Human IL-17F Recombit Protein
• Neutralization dose will vary depending on assay method, cytokine concentration, and cell type
• This antibody should be carefully titrated for optimal performance in the assay of interest
• Endotoxin: Less than 0.001 ng/ug antibody as determined by the LAL assay
• IL-17F (Interleukin 17F, CTLA-8)) is a cytokine belonging to the IL-17 family that is produced by inflammatory cells such as activated T cells, mast cells, and basophils
• IL-17F is involved in allergic airway inflammation, and can induce several cytokines, chemokines, and adhesion molecules in bronchial epithelial cells, vein endothelial cells, fibroblasts, and eosinophils
• IL-17F may be secreted as a homodimer, or a heterodimer with IL17A
• It acts by binding to the type I receptor, IL-17R, aiding recruitment of monocytes and neutrophils at the site of inflammation by increasing chemokine production
• IL-17F also stimulates induction of other pro-inflammatory cytokines TNF alpha, IL-1 beta, IL-6, and IL-8, and reports strongly suggest the involvement of IL-17 in several chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and multiple sclerosis
• TGF-beta (differentiation) and IL-23 (expansion) are required for induction and maintenance of Th17 (IL-17 producing) cells, which in turn induce the other pro-inflammatory cytokines
• IL-17F is produced, and exists, as a homo-dimer, with homology to a herpes virus early protein, is one of the six members (IL-17A-F) of this cytokine family, and is well characterized and highly expressed by activated effector memory T cells
• IL-17F has been found to inhibit the angiogenesis of endothelial cells and induce endothelial cells to produce IL2, TGFB1/TGFB, and monocyte chemoattractant protein-1.